Polymyalgia Rheumatica Clinical Trial
Official title:
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing treatment. A proof of concept study on Rituximab (RTX) vs placebo showed efficacy in 48 vs 21%(p=0.049) in glucocorticoid free remission after 21 weeks (Marsman et al. 2021). Though promising, the short study duration and small sample size require further confirmation. Therefore a larger randomised controlled trial with longer follow up will be performed on RTX efficacy on glucocorticoid free remission in newly diagnosed PMR patients during glucocorticoid taper.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04972968 -
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
|
Phase 2 | |
| Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
| Recruiting |
NCT06460142 -
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
|
||
| Terminated |
NCT03600818 -
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
|
Phase 3 | |
| Completed |
NCT00836810 -
Timed Release Tablet Prednisone in Polymyalgia Rheumatica
|
Phase 2/Phase 3 | |
| Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
| Completed |
NCT03263715 -
A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)
|
Phase 3 | |
| Recruiting |
NCT05935709 -
DANIsh VASculitis Database (DANIVAS)
|
||
| Not yet recruiting |
NCT02985424 -
Polymyalgia Rheumatica and Giant Cell Arteritis
|
N/A | |
| Completed |
NCT00138983 -
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
|
Phase 3 | |
| Recruiting |
NCT06130540 -
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
|
Phase 1 | |
| Recruiting |
NCT05767034 -
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
|
Phase 3 | |
| Terminated |
NCT01821040 -
A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR
|
Phase 3 | |
| Recruiting |
NCT00982332 -
Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica
|
N/A | |
| Recruiting |
NCT05312944 -
Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome
|
||
| Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
| Withdrawn |
NCT02899026 -
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
|
Phase 3 | |
| Recruiting |
NCT03576794 -
Treatment With Leflunomide in Patients With Polymyalgia Rheumatica
|
Phase 3 | |
| Completed |
NCT05681676 -
Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
|
||
| Recruiting |
NCT05435781 -
Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
|
Phase 4 |